Table 1.
Clinical, Biochemical and Angiographic Characteristics of Patients with Stable CAD in the Lp(a) >30 mg/dL Group and in Lp(a) ≦30 mg/dL Group
| Parameters | Lp(a) >30 mg/dL (n=127) | Lp(a) ≦30 mg/dL (n=519) | p-value |
|---|---|---|---|
| Age, years | 63.0±10.7 | 63.7±10.0 | 0.466 |
| Male, n (%) | 85 (66.9) | 337 (64.9) | 0.672 |
| HTN, n (%) | 94 (74.0) | 323 (62.2) | 0.013 |
| DM, n (%) | 27 (21.3) | 88 (17.0) | 0.256 |
| Current smoker, n (%) | 40 (31.5) | 135 (26.0) | 0.213 |
| Family history of CAD, n (%) | 7 (5.5) | 23 (4.4) | 0.604 |
| Current drugs | |||
| ACEIs/ARBs, n (%) | 39 (30.7) | 173 (33.3) | 0.572 |
| CCBs, n (%) | 46 (36.2) | 155 (29.9) | 0.166 |
| Beta-blockers, n (%) | 13 (10.2) | 41 (7.9) | 0.394 |
| Diuretics, n (%) | 15 (11.8) | 65 (12.5) | 0.827 |
| Statins, n (%) | 13 (10.2) | 37 (7.1) | 0.240 |
| Antiplatelet drugs, n (%) | 8 (6.3) | 29 (5.6) | 0.757 |
| Triple vessel disease, n (%) | 41 (32.3) | 119 (22.9) | 0.029 |
| Syntax score ≧23, n (%) | 27 (21.3) | 73 (14.1) | 0.045 |
| Syntax score | 12 (6–21) | 9 (5–17) | 0.006 |
| SBP, mmHg | 130 (120–140) | 130 (120–140) | 0.997 |
| DBP, mmHg | 76 (70–80) | 78 (70–84) | 0.595 |
| ALB, g/L | 40.3 (38.2–43.1) | 40.4 (38.1–42.9) | 0.838 |
| ALT, U/L | 19 (13–29) | 20 (14–31) | 0.202 |
| AST, U/L | 20 (17–26) | 21 (17–28) | 0.301 |
| GGT, U/L | 26 (18–48) | 26 (18–42) | 0.800 |
| TBIL, mg/dL | 0.63 (0.44–0.89) | 0.63 (0.46–0.87) | 0.517 |
| FBG, mg/dL | 95.0 (86.2–110.7) | 96.1 (87.3–108.9) | 0.496 |
| Scr, mg/dL | 0.78 (0.67–0.95) | 0.78 (0.68–0.90) | 0.494 |
| UA, mg/dL | 5.85 (4.80–7.07) | 5.86 (4.97–6.97) | 0.892 |
| TG, mg/dL | 117.8 (90.4–168.3) | 123.2 (88.6–179.9) | 0.812 |
| TC, mg/dL | 170.9 (142.3–219.6) | 160.8 (133.8–191.8) | 0.003 |
| HDL-C, mg/dL | 43.3 (37.1–50.3) | 41.8 (35.6–49.1) | 0.252 |
| LDL-C, mg/dL | 100.1 (76.5–134.5) | 92 (71.1–112.9) | 0.001 |
| Lp(a), mg/dL | 46 (37–64) | 11 (6–19) | 0.000 |
| hsCRP, mg/L | 3.6 (2.0–7.3) | 3.6 (1.6–8.0) | 0.772 |
| WBC, ×103/μL | 6.2 (5.3–7.8) | 6.1 (5.1–7.4) | 0.293 |
| NEU, ×103/μL | 4.0 (3.2–5.0) | 3.7 (3.0–4.7) | 0.143 |
| LYM, ×103/μL | 1.6 (1.2–2.1) | 1.6 (1.3–2.0) | 0.624 |
| MON, ×103/μL | 0.5 (0.4–0.6) | 0.5 (0.4–0.6) | 0.400 |
| HGB, g/L | 137 (125–147) | 135 (125–147) | 0.408 |
| PLT, ×103/μL | 194 (167–238) | 186 (158–221) | 0.106 |
| MHR, ×103/mg | 11.6 (8.7–15.8) | 11.9 (8.5–16.0) | 0.968 |
| SII | 496 (323–718) | 434 (300–642) | 0.113 |
| LVEF, % | 66 (61–71) | 66 (61–70) | 0.626 |
Notes: Values are presented as means ± SD or medians (interquartile ranges) for continuous variables, and as the numbers of patients (%) for categorical variables. p-value < 0.05 are presented with bold characters.
Abbreviations: CAD, coronary artery disease; Lp(a), lipoprotein(a); HTN, hypertension; DM, diabetes mellitus; ACEIs, angiotensin-converting enzyme inhibitors; ARBs, angiotensin receptor blockers; CCBs, calcium channel blockers; SBP, systolic blood pressure; DBP, diastolic blood pressure; ALB, albumin; ALT, alanine aminotransferase; AST, aspartate aminotransferase; GGT, gamma-glutamyl transferase; TBIL, total bilirubin; FBG, fasting blood glucose; Scr, serum creatinine; UA, uric acid; TG, triglyceride; TC, total cholesterol; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; hsCRP, high-sensitivity C-reactive protein; WBC, white blood cell; NEU, neutrophil; LYM, lymphocyte; MON, monocyte; HGB, hemoglobin; PLT, platelet; MHR, monocyte count to high-density lipoprotein cholesterol ratio; SII, systemic immune-inflammation index; LVEF, left ventricular ejection fraction.